Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ).
Shanghai MicroPort MedBot (Group) Co., Ltd. announced a significant projected revenue increase of 70% to 80% for the first half of 2025, driven by strong sales of its surgical robots, particularly the Toumai Laparoscopic Surgical Robot. The company’s strategic focus on globalization and market expansion has also contributed to a more than 40% reduction in net loss, highlighting improved operational efficiency and cost management.
The most recent analyst rating on (HK:2252) stock is a Buy with a HK$9.50 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. operates in the medical technology industry, focusing on the development and commercialization of surgical robots. Its primary products include the Toumai Laparoscopic Surgical Robot, SkyWalker Orthopedic Surgical Robot, and R-ONE Vascular Interventional Surgical Robot, with a market focus on both domestic and international expansion.
Average Trading Volume: 8,555,121
Technical Sentiment Signal: Buy
Current Market Cap: HK$18.67B
For detailed information about 2252 stock, go to TipRanks’ Stock Analysis page.